Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by ScienceFirston Aug 24, 2022 11:42am
163 Views
Post# 34917164

Upcoming efficacy % @360-days

Upcoming efficacy % @360-days
Lets now focus on the 360-days milestone.  For the TR (CR + PR), we currently stand at 39%.
 
Now, 
 
... if 4 patients out of these 18 pending turn CR @360-days, then 13 (5 + 4 + 4) out of 41 patients = 32% @360-days 
... if 5 patients out of these 18 pending turn CR @360-days, then 14 (5 + 4 + 5) out of 41 patients = 34% @360-days
... if 6 patients out of these 18 pending turn CR @360-days, then 15 (5 + 4 + 6) out of 41 patients = 37% @360-days
... if 7 patients out of these 18 pending turn CR @360-days, then 16 (5 + 4 + 7) out of 41 patients = 39% @360-days
... if 8 patients out of these 18 pending turn CR @360-days, then 17 (5 + 4 + 8) out of 41 patients = 41% @360-days
... if 9 patients out of these 18 pending turn CR @360-days, then 18 (5 + 4 + 9) out of 41 patients = 44% @360-days
... if 10 patients out of these 18 pending turn CR @360-days, then 19 (5 + 4 + 10) out of 41 patients = 46% @360-days
... if 11 patients out of these 18 pending turn CR @360-days, then 20 (5 + 4 + 11) out of 41 patients = 49% @360-days
... if 12 patients out of these 18 pending turn CR @360-days, then 21 (5 + 4 + 12) out of 41 patients = 51% @360-days
... if 13 patients out of these 18 pending turn CR @360-days, then 22 (5 + 4 + 13) out of 41 patients = 54% @360-days
... if 14 patients out of these 18 pending turn CR @360-days, then 23 (5 + 4 + 14) out of 41 patients = 56% @360-days
... if 15 patients out of these 18 pending turn CR @360-days, then 24 (5 + 4 + 15) out of 41 patients = 59% @360-days
... if 16 patients out of these 18 pending turn CR @360-days, then 25 (5 + 4 + 16) out of 41 patients = 61% @360-days
... if 17 patients out of these 18 pending turn CR @360-days, then 26 (5 + 4 + 17) out of 41 patients = 63% @360-days
... if 18 patients out of these 18 pending turn CR @360-days, then 27 (5 + 4 + 18) out of 41 patients = 66% @360-days
 
<< Previous
Bullboard Posts
Next >>